Abstract
Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post-infusion CART expansion and persistence and for real-time clinical decision-making. Multiparameter flow cytometry (MFC) enables rapid, live-cell detection with absolute quantification and concurrent immunophenotypic characterization. This review focuses on the practical and technical aspects of flow cytometry–based CAR T-cell monitoring, including selection of CAR detection reagents (target-specific, construct-specific, and target-agnostic strategies), assay optimization, purpose-driven panel design, and matrix-appropriate validation for peripheral blood and other clinically relevant specimens. We also address assay considerations unique to gene-edited allogeneic CAR T-cell products, including the use of surrogate immunophenotypic approaches when construct-specific reagents are unavailable. Finally, we discuss the role of MFC in identifying CAR T-cell clonal expansions and in evaluating suspected secondary hematolymphoid neoplasms in the post-CAR T setting.
| Original language | English (US) |
|---|---|
| Journal | Cytometry Part B - Clinical Cytometry |
| DOIs | |
| State | Accepted/In press - 2026 |
Keywords
- allogeneic CART
- BCMA
- CD19
- chimeric antigen receptor T cells (CART)
- flow cytometry
- ICE enterocolitis
- linker
- scFv
- T-cell lymphoma
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Histology
- Cell Biology
Fingerprint
Dive into the research topics of 'Flow cytometry-based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS